Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Chronic Obstructive Pulmonary Disease-V: Nursing Management01:30

Chronic Obstructive Pulmonary Disease-V: Nursing Management

Nursing management of Chronic Obstructive Pulmonary Disease (COPD) is crucial for providing thorough care and support to patients. Nurses play an integral role in this process through detailed assessment, careful planning, targeted interventions, and ongoing evaluation. Here's an overview of the critical steps in nursing management for COPD.
Assessment
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non-Small Cell Lung Cancer: A Propensity Score-Weighted Analysis.

JCO oncology practice·2026
Same author

Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors.

Clinical lung cancer·2026
Same author

Prevalence of Veteran-reported treatment barriers from the breast and gynecologic oncology system of excellence.

Cancer epidemiology·2026
Same author

Increasing reach of cancer care: provider perspectives on the value and use of teleoncology.

BMC health services research·2026
Same author

SPOP Mutations in Veterans With Prostate Cancer and Outcomes With Doublet and Triplet Therapy in De Novo Metastatic Hormone Sensitive Prostate Cancer.

The Prostate·2026

Related Experiment Video

Updated: Jun 4, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Lung cancer management in 2010.

Apar Kishor Ganti1, Chao H Huang, Mark A Klein

  • 1VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, USA. aganti@unmc.edu

Oncology (Williston Park, N.Y.)
|March 3, 2011
PubMed
Summary
This summary is machine-generated.

Recent lung cancer research highlights new therapies and the IASLC staging system. Targeted agents show promise, but combining them with chemotherapy in all patients was unsuccessful.

Related Experiment Videos

Last Updated: Jun 4, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

  • Oncology
  • Pulmonology
  • Medical Oncology

Background:

  • Lung cancer management has seen significant advancements.
  • The International Association for the Study of Lung Cancer (IASLC) introduced a new staging system in 2010.
  • Novel molecular targets are being identified for therapeutic intervention.

Purpose of the Study:

  • To review recent clinical advances in lung cancer.
  • To discuss the impact of new therapies and staging systems.
  • To evaluate the success of targeted agents and combination strategies.

Main Methods:

  • Literature review of recent clinical trials and studies.
  • Analysis of novel therapeutic targets like EML4-ALK.
  • Evaluation of treatment strategies including targeted agents and chemotherapy.

Main Results:

  • New targeted therapies, such as those for EML4-ALK, show promise in early trials.
  • The adoption of the 2010 IASLC staging system impacts lung cancer classification.
  • Combining targeted agents with chemotherapy in unselected patients has not yielded successful outcomes.

Conclusions:

  • Targeted therapies represent a significant advancement in lung cancer treatment.
  • Future lung cancer care will be shaped by novel agents and personalized approaches.
  • Careful patient selection is crucial for the success of targeted lung cancer therapies.